PALO ALTO, Calif. — Frazier Life Sciences, an investment firm focused on innovative therapeutics, has appointed Charles (Charlie) Fuchs, M.D., M.P.H., as Senior Advisor.
Dr. Fuchs brings extensive experience as an innovator and executive leader across oncology, immunology, and translational medicine, with a track record of advancing programs through global product development and regulatory approvals. Most recently, he served as Senior Vice President and Global Head of Product Development for Oncology and Hematology at Roche, where he led the development and execution of a comprehensive global strategy for the company’s Oncology and Hematology division. In that role, he oversaw portfolio growth, supported the approval of multiple new therapies and indications across cancer and blood disorders, and led the strategic acquisition of external assets to strengthen the portfolio.
“Dr. Fuchs brings a depth of experience across oncology, immunology and global drug development, which will be an invaluable asset as we continue to partner with companies building transformative medicines,” said Jamie Topper, Managing Partner at Frazier Life Sciences. “We are pleased to welcome him to the Frazier team.”
Prior to his work with Genentech and Roche, Dr. Fuchs served as Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital. In that role, he managed an integrated clinical and research operation spanning 16 facilities across New England and played a key role in launching several biotechnology startups rooted in Yale research.
Dr. Fuchs has also served on advisory boards for numerous cancer centers, foundations, biotechnology companies, and pharmaceutical organizations, and co-founded EvolveImmune Therapeutics. Earlier in his academic career, he was Professor of Medicine at Harvard Medical School and served as Chief of the Gastrointestinal Oncology Division at Dana-Farber Cancer Institute, as well as the Robert T. and Judith B. Hale Chair in Pancreatic Cancer.
“The Frazier Life Sciences team has demonstrated a long, successful history of supporting companies at critical moments in their evolution,” said Dr. Fuchs. “I look forward to guiding the entrepreneurs who are seeking to translate cutting edge biology into meaningful therapies for patients.”
Dr. Fuchs received his M.D. and M.P.H. from Harvard University and holds a B.A. in Biochemistry from the University of Pennsylvania. He completed postgraduate training in Internal Medicine, Medical Oncology, and Hematology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston.
